ArticleCancer medicine2023
Financial toxicity of patients with lung cancer in China: Results from a National Survey Study.
Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Financial toxicity among patients with lung cancer: a systematic review and meta-analysis.Frontiers in public health · 2026Pooled it
- Decision conflict, psychological resilience, and financial toxicity in early-stage non-small cell lung cancer in China: A latent profile and mediation analysis.Asia-Pacific journal of oncology nursing · 2026Article
- Financial Distress and Its Determinants in Rheumatoid Arthritis.Arthritis care & research · 2026Article
- Prevalence of financial toxicity and construction of a risk prediction model for lung cancer patients at 6 months after discharge.Frontiers in medicine · 2026Article
- Disparities in cancer-related financial toxicity across economically diverse provinces in China: A multi-center cross-sectional study.Asia-Pacific journal of oncology nursing · 2025Article
- Health-related quality of life and financial toxicity in Chinese patients with multiple myeloma: a two-year real-world multicentre study.Health and quality of life outcomes · 2025Article
- Potential profile analysis of financial toxicity and its related factors among lung cancer patients.BMC cancer · 2025Article
- Financial Toxicity in Older Adults With Cancer and Their Caregivers.JCO oncology practice · 2025Review
- Assessment of the financial toxicity in patients with differentiated thyroid cancer: a cross-sectional study in western China.Frontiers in public health · 2025Article
- Factors influencing economic toxicity and coping strategies in lung cancer patients: A scoping review.Heliyon · 2024Article
- Beyond Medical Bills: High Prevalence of Financial Toxicity and Diverse Management Strategies Among Vietnamese Patients With Cancer.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2024Article
- Financial toxicity and its risk factors among patients with cancer in China: A nationwide multisite study.Asia-Pacific journal of oncology nursing · 2024Article
- Determination of a cut-off COmprehensive Score for financial Toxicity (COST) for identifying cost-related treatment nonadherence and impaired health-related quality of life among Chinese patients with cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Health insurance as a moderator in the relationship between financial toxicity and medical cost-coping behaviors: Evidence from patients with lung cancer in China.Cancer medicine · 2024Article
- How social support influences learned helplessness in lung cancer patients: the chain mediation role of individual resilience and self-efficacy.Frontiers in psychology · 2024Article
- Influence of Financial Toxicity on the Quality of Life in Lung Cancer Patients Undergoing Immunotherapy: The Mediating Effect of Self-Perceived Burden.Cancer management and research · 2024Article
- Heterogeneity of financial toxicity and associated risk factors for older cancer survivors in China.iScience · 2023Article
- Financial toxicity of patients with lung cancer in China: Results from a National Survey Study.Cancer medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo develop a comprehensive understanding of financial toxicity (FT) among patients with lung cancer in China and the major factors affecting FT.
methodsDrawing from a national cross-sectional survey, which used the validated comprehensive score for financial toxicity (COST) questionnaire, we estimated the prevalence and degree of FT. Patient coping actions were investigated. Pearson's chi tests and multinomial logistic regression were used to evaluate the predictors of FT in patients with lung cancer.
resultsThe median score of FT was 20 (scored on a range of 0-44, with lower scores indicating more severe toxicity). Altogether, 77% of the sample patients had FT (COST <26), 54.5% had mild FT (COST 14-25), and 22.5% had moderate and severe FT (COST 0-13). Living in the less-developed western region of China, being male, having a lower educational level, lower annual family income, and advanced stage or worse self-reported health status were significantly related to higher FT than their counterparts (p < 0.05). Patients with higher FT tended to have a lower level of medical compliance, a higher risk of incurring debts, and reduced living expenditures relative to those with lower FT.
conclusionDespite China's remarkable progress in the past two decades with regard to Universal Healthcare Coverage, FT still presents a serious challenge for patients with lung cancer. Keen attention must be paid to reducing the disproportionate high financial risks of patients with low socioeconomic status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.